|
ANAPC1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.14720000008195E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.09389999999976E-05 |
| Normal-vs-Stage2 |
1.029880E-04 |
| Normal-vs-Stage3 |
5.77620000052903E-07 |
| Normal-vs-Stage4 |
1.81940999999242E-05 |
| Stage1-vs-Stage2 |
4.790000E-01 |
| Stage1-vs-Stage3 |
2.447400E-01 |
| Stage1-vs-Stage4 |
4.080600E-01 |
| Stage2-vs-Stage3 |
8.969000E-01 |
| Stage2-vs-Stage4 |
9.435000E-01 |
| Stage3-vs-Stage4 |
9.567600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.90859999996229E-06 |
| Normal-vs-AfricanAmerican |
1.311860E-02 |
| Normal-vs-Asian |
1.203620E-04 |
| Caucasian-vs-AfricanAmerican |
6.126000E-01 |
| Caucasian-vs-Asian |
7.431400E-01 |
| AfricanAmerican-vs-Asian |
4.875000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.58650000201288E-08 |
| Normal-vs-Female |
4.46499999995353E-06 |
| Male-vs-Female |
1.484440E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.829900E-04 |
| Normal-vs-Age(41-60Yrs) |
1.61230000017554E-07 |
| Normal-vs-Age(61-80Yrs) |
2.17179999995043E-06 |
| Normal-vs-Age(81-100Yrs) |
1.238250E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.469800E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.160800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.653800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.258800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.387400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.730200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.380600E-01 |
| Classical-VS-Follicular |
3.425400E-04 |
| Classical-VS-Other |
1.195430E-01 |
| Classical-VS-Normal |
1.038260E-04 |
| Tall-VS-Follicular |
2.199400E-01 |
| Tall-VS-Other |
3.127600E-01 |
| Tall-VS-Normal |
7.984300E-04 |
| Follicular-VS-Other |
7.328600E-01 |
| Follicular-VS-Normal |
1.57889999963245E-08 |
| Other-VS-Normal |
2.881200E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.9595000000372E-07 |
| Normal-vs-N1 |
4.68040000001224E-06 |
| N0-vs-N1 |
6.847000E-01 |
|
|
